Italia markets close in 2 hours 41 minutes

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
17,81-0,42 (-2,30%)
Alla chiusura: 04:00PM EST
18,44 +0,63 (+3,54%)
Preborsa: 08:15AM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente18,23
Aperto18,86
Denaro18,00 x 1200
Lettera18,50 x 1100
Min-Max giorno17,62 - 19,83
Intervallo di 52 settimane16,37 - 73,03
Volume3.796.748
Media Volume1.537.827
Capitalizzazione1,218B
Beta (5 anni mensile)1,91
Rapporto PE (ttm)N/D
EPS (ttm)-3,23
Prossima data utili23 feb 2022 - 28 feb 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A49,71
  • GlobeNewswire

    Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference

    James C. Mullen James C. Mullen, Chairman, President, and Chief Executive Officer of Editas Medicine Anticipated 2022 milestones include initial clinical data for EDIT-301 in sickle cell disease by year-end, dosing of first TDT patient with EDIT-301, initiation of pediatric high-dose cohort for EDIT-101 in LCA10, and a clinical data update on EDIT-101 in the second half of 2022 Company announces new development candidates EDIT-103 for RHO-adRP and EDIT-202 multiplexed iNK cell therapy for solid

  • GlobeNewswire

    Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview and update at the 40th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 12, 2022, at 10:30 a.m. ET A live webcast of the presentation will be available on the Investors section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available on the website fo

  • GlobeNewswire

    Dr. Jessica Hopfield Appointed to Berkeley Lights Board of Directors

    Addition of Experienced Independent Director with Accomplished Business Record Underscores Berkeley Lights Board of Directors’ Commitment to Delivering Value for ShareholdersEMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced the appointment of Jessica Hopfield, Ph.D. to the Berkeley Lights’ Board of Directors as an independent director, effective December 15, 2021. "Dr. Hopfield is a respected and accomplis